Tamoxifen maculopathy in a male patient
Shreyas Temkar, Amar Pujari, Divya Agarwal, Rohan Chawla

DESCRIPTION

Case description
A 28-year-old male patient presented with the history of blurring of vision in both the eyes for the past 3 months. The patient was a diagnosed case of desmoid fibromatosis of the right axilla 8 years back. The tumour was initially debulked followed by four cycles of systemic chemotherapy, after which patient was symptom-free for 3 years. The patient noticed an increment in the tumour size, for which he consulted another oncologist. A repeat biopsy was done, which proved the same findings. The patient was started on a combination of tamoxifen 80mg/day and celecoxib 200mg/day. He had received tamoxifen at a cumulative dose of 116g over 4 years. Examination in our clinic revealed visual acuity of 20/20 in both eyes with unremarkable anterior chamber findings. Intraocular pressure was 14 and 16mm Hg in right and left eye, respectively. Fundus showed bilateral crystalline refractile deposits in the macula, rest of the retinal and optic disc examination was within normal limits (figure 1A and B). Red-free images highlighted the presence of intraretinal refractile deposits (figure 1C and D). Spectral domain optical coherence tomography of the retina showed the deposits located in the inner retinal layers with an intact outer retina and pigment epithelium. There was no evidence of intraretinal oedema/cavitation (figure 1E and F). Humphrey visual field 10–2, colour vision and contrast sensitivity were within normal limits. However, the patient in consult with the oncologist was keen on discontinuation of tamoxifen and the patient reported subjective improvement in vision after discontinuation.

Discussion
Tamoxifen is a selective oestrogen receptor modulator commonly used as maintenance therapy in female breast carcinomas. Ocular side effects of tamoxifen include retinopathy, cataract, corneal deposits and optic neuropathy.1 Retinal manifestations include bilateral refractive crystalline deposits around the perifoveal area with or without associated macular oedema. The cause is not exactly known but could be due to axonal degeneration or inhibition of lipid metabolism leading to deposition of toxic lipid-drug complexes in the lysosomes. The noted duration between the initiations of medication to obvious visual symptoms varies from 2 to 5 years with a prevalence varying from 0.6% to 3.1%.2,3 Central visual acuity and colour vision impairment mandate the discontinuation of the medication. In tamoxifen retinopathy cases, retinal imaging may be normal or may show cavitation of the outer retinal layers and partial thickness macular hole. In our case, there was only blurring of vision but the optical coherence tomography did not reveal any form of photoreceptor, pigment epithelium, outer retinal layers disruption or pigment epithelium. Also, visual fields, colour vision and contrast sensitivity was within normal limits. However, the patient in consult with the oncologist was keen on discontinuation of tamoxifen and the patient reported subjective improvement in vision after discontinuation.

There is only one case report of occurrence of tamoxifen retinopathy in a male patient. This 68-year-old patient was treated for a non-breast carcinoma (un-resectable haepatocellular carcinoma) and had received a cumulative dose of 60g over 33 months.4 In contrast to this case, our patient was younger and received about 116g over 4 years. This point probably highlights that the chances of toxicity are higher in older age patients at a lesser cumulative dose. Also, prior retinal toxic chemotherapeutic agents may confound the findings/manifestations.

Contributors All authors: evaluated the case in detail, after critically analysing the educational value of the case, and together wrote the report.

Competing interests None declared.

Patient consent Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

Learning points

► Tamoxifen retinopathy in male patients is rare occurrence. Patients on tamoxifen for breast as well as non-breast carcinomas need ocular evaluation at the baseline and at regular intervals even after stoppage of medication.
► Even though there is less evidence to suggest significant visual loss due to retinopathy or cataract, these reversible issues need to be addressed at the earliest to avoid visual comorbidities.
► Access all the published articles
► Re-use any of the published material for personal use and teaching without further permission

For information on Institutional Fellowships contact consortiasales@bmjgroup.com
Visit casereports.bmj.com for more articles like this and to become a Fellow